Wednesday, June 22, 2022
    HomeHealthLilly and Roche are also losers in the Medicare Alzheimer's decision

    Lilly and Roche are also losers in the Medicare Alzheimer’s decision


    Rise and shine, one other busy day is on the way in which. Nonetheless, that is additionally shaping up as an exquisite day as properly, given the clear and sunny skies — and scrumptious breezes — enveloping the Pharmalot campus this morning. This requires celebration with a cup of stimulation, and we’re opening a brand new bundle of Pumpkin Spice for the event. Autumn, in any case, is simply eight months away. What’s upon us proper now, nevertheless, is our ever-growing to-do listing. Sound acquainted? So … listed below are some objects of curiosity. Have an important day, everybody. …

    Medicare could have launched a plan to limit entry to the controversial Biogen (BIIB) Alzheimer’s drug, however the greatest losers may very well be different drug makers readying remedies for the debilitating illness, STAT explains. Each Eli Lilly (LLY) and Roche (RHHBY) have such remedies within the works, and Biogen has two extra, developed in partnership with Eisai, as properly. “Whereas a lot of the main focus has been on what this implies for [the Biogen drug], this suggestion impacts a whole class of drug and is prone to end in a extra aligned effort by stakeholders as they attempt to affect the ultimate model,” mentioned a advisor for drug makers, together with Biogen.

    Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!


    Source link

    Related articles

    Stay Connected


    Latest posts